Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 5 of 1,261
  1. WO 2026039538

    MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS

    TRISHULA THERAPEUTICS INC [US] · Granted Feb 19, 2026 · Expires Feb 14, 2046

    granted
  2. WO 2026039512

    INHIBITEURS DE KRAS

    BRISTOL MYERS SQUIBB CO [US] · Granted Feb 19, 2026 · Expires Feb 14, 2046

    granted
  3. WO 2026039321

    MÉTHODES DE TRAITEMENT DU CANCER DE LA PROSTATE

    AMGEN INC [US] · Granted Feb 19, 2026 · Expires Feb 14, 2046

    granted
  4. WO 2026039306

    BÉTAÏNE ET FOLATE POUR FAVORISER LA MATURATION DU CERVEAU D'UN NOURRISSON

    ABBOTT LAB [US] · Granted Feb 19, 2026 · Expires Feb 14, 2046

    granted
  5. US 20260042800

    ANTIMICROBIAL PEPTIDOMIMETICS

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Granted Feb 12, 2026 · Expires Feb 7, 2046

    granted
  6. WO 2026035787

    MACROCYLES DE PROTÉASE DE TRAITEMENT SPÉCIFIQUE DE L'UBIQUITINE (USP1)

    BRISTOL MYERS SQUIBB CO [US] · Granted Feb 12, 2026 · Expires Feb 7, 2046

    granted
  7. WO 2026032865

    SEL D'UN INHIBITEUR DE SOS-1

    BAYER AG [DE] · Granted Feb 12, 2026 · Expires Feb 7, 2046

    granted
  8. WO 2026033380

    PROCESSUS DE PRÉPARATION DE COMPLEXES OLIGOSACCHARIDIQUES

    BIONTECH SE [DE] · Granted Feb 12, 2026 · Expires Feb 7, 2046

    granted
  9. WO 2026033885

    POLYTHÉRAPIE FAISANT INTERVENIR DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET AGENTS STABILISANT OU AUGMENTANT L'EXPRESSION DE CLDN18.2

    ASTELLAS PHARMA INC [JP] · Granted Feb 12, 2026 · Expires Feb 7, 2046

    granted
  10. EP 4691463

    VERFAHREN ZUR PRÄVENTION ODER BEHANDLUNG VON HERZVERSAGEN BEI EINEM PATIENTEN MIT (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDIN-3-CARBOXAMID

    BAYER AG [DE] · Granted Feb 11, 2026 · Expires Feb 6, 2046

    granted
  11. US 20260034134

    TREATMENT OF CANCER WITH METASTASES IN THE CENTRAL NERVOUS SYSTEM

    BOEHRINGER INGELHEIM INT [DE] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  12. US 20260035358

    WEE1 DEGRADING COMPOUNDS AND USES THEREOF

    BRISTOL MYERS SQUIBB CO [US] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  13. US 20260035439

    Anti-Sars-COV-2 Antibodies and Uses Thereof

    ABBVIE INC [US] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  14. WO 2026030375

    NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

    GENZYME CORP [US] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  15. WO 2026027695

    COMPOSITIONS ET PROCÉDÉS

    BIONTECH SE [DE] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  16. WO 2026029046

    LIPIDE D'URÉE OU DE CARBAMATE AYANT UN GROUPE CYCLIQUE DANS UNE CHAÎNE LATÉRALE, NANOPARTICULES LIPIDIQUES DE CELUI-CI ET COMPOSITION PHARMACEUTIQUE ASSOCIÉE

    ASTELLAS PHARMA INC [JP] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  17. WO 2026027669

    BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB

    ALFASIGMA SPA [IT] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  18. WO 2026027375

    HYDROXY-DIHYDROPYRIDINON CARBOXAMIDE ALS SCHÄDLINGSBEKÄMPFUNGSMITTEL

    BAYER AG [DE] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  19. WO 2026027759

    AGENTS ET MÉTHODES POUR UNE ADMINISTRATION CIBLÉE À DES CELLULES

    BIONTECH SE [DE] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  20. US 20260027049

    AVACOPAN FORMULATIONS

    AMGEN INC [US] · Granted Jan 29, 2026 · Expires Jan 24, 2046

    granted
  21. WO 2026021698

    PARTICULE D'ACIDE NUCLÉIQUE

    BIONTECH SE [DE] · Granted Jan 29, 2026 · Expires Jan 24, 2046

    granted
  22. WO 2026024938

    MÉTHODES DE RÉDUCTION DE LA TRANSMISSION INTRA-UTÉRINE D'UNE INFECTION À SALMONELLA DUBLIN

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Jan 29, 2026 · Expires Jan 24, 2046

    granted
  23. WO 2026025082

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Granted Jan 29, 2026 · Expires Jan 24, 2046

    granted
  24. US 12533358

    Methods of treatment with elinzanetant

    BAYER CONSUMER CARE AG [CH] · Granted Jan 27, 2026 · Expires Jan 22, 2046

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.